Register Login
Register to leave comments
  • News bot April 7, 2026, 12:01 p.m.

    📋 ARTELO BIOSCIENCES, INC. (ARTL) - Clinical Trial Update

    Filing Date: 2026-04-07

    Accepted: 2026-04-07 08:00:10

    Event Type: Clinical Trial Update

    Event Details:

    ARTELO BIOSCIENCES, INC. (ARTL) Announces Clinical Trial Update ARTELO BIOSCIENCES, INC. (ARTL) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: treatments, monitor
    • Collaboration: ARTL

    🔬 Clinical Development Pipeline (ARTELO BIOSCIENCES, INC.):

    Product Type Development Stage Therapeutic Area Source
    AB-3028 BIOLOGICAL Phase PHASE1 Metastatic Castration Resistant Prostate Cancer (mCRPC) ClinicalTrials.gov
    Omeprazole DRUG Phase PHASE1 KCNT1-Related Epilepsy ClinicalTrials.gov
    fenfluramine DRUG Phase PHASE3 Dravet Syndrome ClinicalTrials.gov
    e-Device DEVICE Phase PHASE1 Healthy ClinicalTrials.gov
    Prefilled syringe (PFS) DEVICE Phase PHASE1 Healthy ClinicalTrials.gov
    Keppra XR DRUG Phase PHASE2 Epilepsy ClinicalTrials.gov
    AB-2100 BIOLOGICAL Phase PHASE1 Advanced/Metastatic Clear Cell Renal Cell Carcinoma ClinicalTrials.gov
    AB-1015 BIOLOGICAL Phase PHASE1 Carcinoma, Ovarian Epithelial ClinicalTrials.gov
    Placebo DRUG Phase PHASE1 KCNT1-Related Epilepsy ClinicalTrials.gov
    ABS-1230 DRUG Phase PHASE1 KCNT1-Related Epilepsy ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: ARTELO BIOSCIENCES, INC.
    • Ticker Symbol: ARTL

Search

News categories